Background And Purpose: Ventricular assist devices (VADs) have advanced the management of end-stage heart failure. However, these devices are associated with hemorrhagic and thrombotic complications, including stroke. We assessed the incidence, risk factors, and outcomes of ischemic and hemorrhagic stroke after VAD placement.
Methods: Using administrative claims data from acute care hospitals in California, Florida, and New York from 2005 to 2013, we identified patients who underwent VAD placement, defined by the International Classification of Diseases, Ninth Revision, Clinical Modification code 37.66. Ischemic and hemorrhagic strokes were identified by previously validated coding algorithms. We used survival statistics to determine the incidence rates and Cox proportional hazard analyses to examine the associations.
Results: Among 1813 patients, we identified 201 ischemic strokes and 116 hemorrhagic strokes during 3.4 (±2.0) years of follow-up after implantation of a VAD. The incidence of stroke was 8.7% per year (95% confidence interval [CI], 7.7-9.7). The annual incidence of ischemic stroke (5.5%; 95% CI, 4.8-6.4) was nearly double that of hemorrhagic stroke (3.1%; 95% CI, 2.6-3.8). Women faced a higher hazard of stroke than men (hazard ratio, 1.6; 95% CI, 1.2-2.1), particularly hemorrhagic stroke (hazard ratio, 2.2; 95% CI, 1.4-3.4). Stroke was strongly associated with subsequent in-hospital mortality (hazard ratio, 6.1; 95% CI, 4.6-7.9).
Conclusions: The incidence of stroke after VAD implantation was 8.7% per year, and incident stroke was strongly associated with subsequent in-hospital mortality. Notably, ischemic stroke occurred at nearly twice the rate of hemorrhagic stroke. Women seemed to face a higher risk for hemorrhagic stroke than men.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5079813 | PMC |
http://dx.doi.org/10.1161/STROKEAHA.116.014049 | DOI Listing |
J Interv Card Electrophysiol
January 2025
Cardiovascular Department, University of Texas Medical Branch, Galveston, TX, USA.
Background: Ventricular tachycardia (VT) in patients with cardiac sarcoidosis (CS) can lead to sudden cardiac death. The role of ventricular tachycardia ablation (VTA) in CS has been investigated in a few small, single-center, and larger observational studies, but the evidence still needs to be provided. This study aimed to investigate the clinical outcomes of VTA in patients with CS admitted with a diagnosis of VT.
View Article and Find Full Text PDFActa Neurochir (Wien)
January 2025
Department of Neurosurgery, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea.
Purpose: Bypass surgery is regarded as the standard treatment option for symptomatic and hemodynamically unstable moyamoya disease (MMD). However, there is ongoing debate about the most effective type of bypass surgery. We aimed to analyze the long-term outcomes of combined and indirect bypasses for MMD patients through intra-individual comparisons.
View Article and Find Full Text PDFBackground: Microhemorrhages and superficial siderosis (SS) have been reported in patients with mild cognitive impairment (MCI) and dementia, especially in the context of Alzheimer's disease (AD) and cerebrovascular disease. Cerebral amyloid angiopathy and small vessel disease (SVD) have both been implicated in microhemorrhages and SS but their prevalence in those with MCI and dementia and their relationship to SVD is unknown.
Method: We conducted a retrospective chart review of patients with MCI or dementia that had undergone MRI scans from 2014 To 2023.
Alzheimers Dement
December 2024
UCLA Fielding School of Public Health, University of California, Los Angeles, CA, USA.
Background: Acute stroke may increase dementia risk. Previous work has not accounted for time-varying covariates that could increase risk of stroke and dementia over time, and there has been very limited evidence on the effect in Asian Americans. We aimed to estimate the effect of incident stroke on dementia risk over 10 years of follow-up among Asian American and White older adults in Northern California considering time-varying covariates.
View Article and Find Full Text PDFBackground: NA-831 is a candidate for the treatment of Alzheimer's Disease (AD). NA-911 is an analog of NA-831, serving as an IGF-1 and GLP-1 agonists. Animal studies of NA-911 are evaluated for the treatment of by hypoxic-ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders METHOD: For NA-831: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!